CRESS | $234,000 | (Feb 21, 2025)
Safe Intelligence | $5,253,443 | (Feb 21, 2025)
Reverb Therapeutics | $21,000,000 | (Feb 21, 2025)
Certified by Founder
Lodge
AltPep
start up
United States
- Seattle, Washington
- 26/06/2023
- Series B
- $53,000,000
AltPep develops early disease-modifying treatments and detection tools for amyloid diseases by targeting one of the earliest molecular triggers – toxic soluble oligomers. These oligomers are associated with many diseases, including neurodegenerative diseases and type 2 diabetes. Decades of scientific research by the Daggett Research Group culminated in the discovery of a novel protein structure, alpha-sheet, the foundation of our innovative approach.
Our lead program aims to identify Alzheimer’s Disease long before symptoms occur and then neutralize the toxic soluble oligomers associated with the disease.
- Industry Biotechnology
- Website https://www.altpep.com/
- LinkedIn https://www.linkedin.com/company/altpep/
QuSecure | $28,000,000 | (Feb 21, 2025)
AheadComputing | $21,500,000 | (Feb 21, 2025)
Together AI | $30,000,000 | (Feb 21, 2025)
Kodesage | $2,300,000 | (Feb 21, 2025)
OpenEvidence | Undisclosed Amount | (Feb 21, 2025)
Oso Semiconductor | $5,200,000 | (Feb 21, 2025)
EnPlusOne Biosciences | $10,000,000 | (Feb 21, 2025)
Pinkfish | $7,600,000 | (Feb 21, 2025)
Esperto Medical | Undisclosed Amount | (Feb 21, 2025)